195 related articles for article (PubMed ID: 18983834)
1. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
Hough LB; Svokos K; Nalwalk JW
Brain Res; 2009 Jan; 1247():62-70. PubMed ID: 18983834
[TBL] [Abstract][Full Text] [Related]
2. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
Salussolia CL; Nalwalk JW; Hough LB
Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267
[TBL] [Abstract][Full Text] [Related]
3. Significance of cannabinoid CB1 receptors in improgan antinociception.
Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB
J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.
Nalwalk JW; Svokos K; Hough LB
Eur J Pharmacol; 2006 Nov; 549(1-3):79-83. PubMed ID: 16989809
[TBL] [Abstract][Full Text] [Related]
6. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.
Hough LB; de Esch IJ; Janssen E; Phillips J; Svokos K; Kern B; Trachler J; Abood ME; Leurs R; Nalwalk JW
Neuropharmacology; 2006 Sep; 51(3):447-56. PubMed ID: 16806300
[TBL] [Abstract][Full Text] [Related]
8. A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic.
Svokos K; Nalwalk JW; Leurs R; Menge WM; Timmerman H; Hough LB
Brain Res; 2001 Dec; 923(1-2):12-9. PubMed ID: 11743967
[TBL] [Abstract][Full Text] [Related]
9. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.
Hough LB; Nalwalk JW; Phillips JG; Kern B; Shan Z; Wentland MP; de Esch IJ; Janssen E; Barr T; Stadel R
Neuropharmacology; 2007 Apr; 52(5):1244-55. PubMed ID: 17336343
[TBL] [Abstract][Full Text] [Related]
10. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Palazzo E; Luongo L; Bellini G; Guida F; Marabese I; Boccella S; Rossi F; Maione S; de Novellis V
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):148-61. PubMed ID: 22483283
[TBL] [Abstract][Full Text] [Related]
11. Activation of brain stem nuclei by improgan, a non-opioid analgesic.
Nalwalk JW; Svokos K; Taraschenko O; Leurs R; Timmerman H; Hough LB
Brain Res; 2004 Sep; 1021(2):248-55. PubMed ID: 15342273
[TBL] [Abstract][Full Text] [Related]
12. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
13. Diabetic thermal hyperalgesia: role of TRPV1 and CB1 receptors of periaqueductal gray.
Mohammadi-Farani A; Sahebgharani M; Sepehrizadeh Z; Jaberi E; Ghazi-Khansari M
Brain Res; 2010 Apr; 1328():49-56. PubMed ID: 20211611
[TBL] [Abstract][Full Text] [Related]
14. Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats.
Escobar W; Ramirez K; Avila C; Limongi R; Vanegas H; Vazquez E
Eur J Pain; 2012 May; 16(5):676-89. PubMed ID: 22337336
[TBL] [Abstract][Full Text] [Related]
15. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat.
de Novellis V; Mariani L; Palazzo E; Vita D; Marabese I; Scafuro M; Rossi F; Maione S
Neuroscience; 2005; 134(1):269-81. PubMed ID: 15953687
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception.
Palazzo E; Marabese I; de Novellis V; Oliva P; Rossi F; Berrino L; Rossi F; Maione S
Neuropharmacology; 2001 Mar; 40(3):319-26. PubMed ID: 11166324
[TBL] [Abstract][Full Text] [Related]
17. Absence of 5-HT3 and cholinergic mechanisms in improgan antinociception.
Nalwalk JW; Svokos K; Leurs R; Hough LB
Pharmacol Biochem Behav; 2005 Mar; 80(3):505-10. PubMed ID: 15740793
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive activity of CC44, a biotinylated improgan congener.
Hoerbelt P; Nalwalk JW; Phillips JG; Wentland MP; Shan Z; Hough LB
Eur J Pharmacol; 2013 Aug; 714(1-3):464-71. PubMed ID: 23834775
[TBL] [Abstract][Full Text] [Related]
19. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
20. Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Godoi MM; Junior HZ; da Cunha JM; Zanoveli JM
Pharmacol Biochem Behav; 2020 Jul; 194():172938. PubMed ID: 32376258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
